Integrated Research Limited provided revenue guidance for the full year 2023. Subject to audit, the company expected the TCV result to translate into reported statutory revenue in the range of $39 million - $42 million for the period, an increase of 1% - 9% on the pcp. On a pro-forma basis, revenue is anticipated to be in the range of $36 million - $38 million, down -6% - 0% on the pcp, reflecting lower recurring (licence) revenue.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.42 AUD | +5.00% | +10.53% | +16.67% |
Mar. 06 | Cathy Aston Resigns as Director of Integrated Research Limited, Effective 31 March 2024 | CI |
Feb. 22 | Transcript : Integrated Research Limited, H1 2024 Earnings Call, Feb 22, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.67% | 45.36M | |
+5.08% | 2,935B | |
+1.41% | 79.66B | |
+0.80% | 74.71B | |
-16.29% | 52.02B | |
+28.83% | 49.26B | |
-27.36% | 44.97B | |
+18.65% | 41.74B | |
+54.79% | 36.02B | |
-11.31% | 24.35B |
- Stock Market
- Equities
- IRI Stock
- News Integrated Research Limited
- Integrated Research Limited Provides Revenue Guidance for the Full Year 2023